ecancermedicalscience

Erratum

Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayeasian network meta-analysis

12 Oct 2021
Victor Hugo Fonseca de Jesus, Rachel P Riechelmann

Throughout the text, please consider that the primary outcome of the PRODIGE24 trial was disease-free survival, and not overall survival.

Related Articles

Moushumi Suryavanshi, Prashant Mehta, Manoj Kumar, Saphalta Bhagmar, Vidit Kapoor, Dushyant Kumar, Sweta Mishra, Bhawna Chauhan
Ariel Cherro, Laura Aresca, María Susana Ciruzzi, Alejo Agranatti, María Fernanda Montaña, Cynthia Frahne, Jaqueline Cimerman
Koreddi A Dora, Vaka Rajashekhar, Mahadevapura R Kaushik, Gaurav Vora, Arti Sarin, Amol Patel
Agnes Chipo Tererai, Margaret Borok, Zvavahera Mike Chirenje, Liz Gwyther, Lindsay Farrant, Ntokozo Ndlovu, Simbarashe Rusakaniko